Melanoma

Expansion and characterization of tumor-infiltrating lymphocytes from human sarcoma
MacLean Hall, John Mullinax, Erica Royster, Angela Reagan, Ricardo Gonzalez, Jose Pimiento, Shari Pilon-Thomas, Amod Sarnaik

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P19; DOI: 10.1186/2051-1426-3-S2-P19
Previously defined 53 immune gene panel predicts melanoma survival using The Cancer Genome Atlas (TCGA)
Robyn Gartrell, Qian Yingzhi, Lopez Gonzalo, Fu Yichun, White-Stern Ashley, Bansal Mukesh, Sivendran Shanthi, Califano Andrea, Chang Rui, Saenger Yvonne

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P283; DOI: 10.1186/2051-1426-3-S2-P283
Adjuvant treatment of early-stage melanoma by local i.d. administration of low-dose CpG-B and GM-CSF increases recurrence-free survival: long-term follow-up of three randomized clinical trials
Tanja D de Gruijl, Bas D Koster, Mari FCM van den Hout, Berbel JR Sluijter, Barbara G Molenkamp, Ronald JCLM Vuylsteke, Paul AM van Leeuwen, Rik J Scheper, Petrousjka van den Tol, Alfons van den Eertwegh

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P201; DOI: 10.1186/2051-1426-3-S2-P201
Stable disease, diagnosis and dose are prognostic factors for survival after interleukin-2 immunotherapy
Nathan H Kwan, Brittany A Ockenfels, Charmi Patel, Gerald P Miletello, Paula R Brantley

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P138; DOI: 10.1186/2051-1426-3-S2-P138
Unique neoantigens expressed by melanomas and common epithelial cancers presented by multiple HLA alleles can be efficiently identified utilizing peptide prediction algorithms
Kasia Trebska-Mcgowan, Mini Bharathan, Jared J Gartner, Todd D Prickett, Steven A Rosenberg, Paul F Robbins

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P57; DOI: 10.1186/2051-1426-3-S2-P57
Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines
Robert O Dillman, Edward McClay, Thomas Amatruda, George Semeniuk, Clark Haskins, Robert Weber, David Burtzo, Carol DePriest, Denysha Carbonell, Andrew Cornforth

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P202; DOI: 10.1186/2051-1426-3-S2-P202
Pre-treatment patient selection for nivolumab benefit based on serum mass spectra
Jeffrey Weber, Alberto J Martinez, Heinrich Roder, Joanna Roder, Krista Meyer, Senait Asmellash, Julia Grigorieva, Maxim Tsypin, Carlos Oliveira, Arni Steingrimsson, Kevin Sayers, Antonella Bacchiocchi, Mario Sznol, Ruth Halaban, Harriet Kluger

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P103; DOI: 10.1186/2051-1426-3-S2-P103
A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
Jan Baughman, Deryk Loo, Francine Chen, Paul Moore, Ezio Bonvini, James Vasselli, Jon Wigginton, Roger Cohen

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P177; DOI: 10.1186/2051-1426-3-S2-P177
Pre-clinical development of the human CD40 agonistic antibody ADC-1013
Per Norlén, Niina Veitonmäki, Karin Enell Smith, Thomas H Tötterman, Sara M Mangsbo, Christina Furebring, Peter Ellmark

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P185; DOI: 10.1186/2051-1426-3-S2-P185
Genome editing of tumor specific T cells for sustained functionality in a suppressive tumor microenvironment
Sara R Pedersen, Per Thor Straten

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P43; DOI: 10.1186/2051-1426-3-S2-P43

Main menu

Melanoma

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Melanoma

Pages